New PCSK9 Antibody Cuts LDL by 66% in Statin-Intolerant Chinese Patients
Ongericimab slashed LDL cholesterol by over 66% vs placebo in a phase 3 trial, offering a promising option for patients who can't tolerate statins.
Summary
For people who cannot tolerate statins — the most widely prescribed cholesterol drugs — finding effective alternatives is critical for heart disease prevention. A new phase 3 clinical trial tested ongericimab, a PCSK9-blocking antibody, in Chinese patients with high cholesterol or mixed dyslipidemia. Over 12 weeks, ongericimab reduced LDL cholesterol by 66.2% compared to placebo, with benefits sustained for a full year. The drug also significantly lowered other cardiovascular risk markers including ApoB, non-HDL cholesterol, total cholesterol, and Lp(a). Side effects were comparable to placebo, suggesting a favorable safety profile. This is the first phase 3 study validating a PCSK9 inhibitor specifically in Chinese statin-intolerant patients, potentially expanding treatment options for a large and underserved population.
Detailed Summary
Elevated LDL cholesterol remains one of the most modifiable risk factors for cardiovascular disease, yet a significant minority of patients cannot tolerate statins due to muscle-related side effects or other adverse reactions. For these individuals, alternative lipid-lowering therapies are urgently needed — particularly in large populations like China where cardiovascular disease rates are rising.
This randomized, double-blind, placebo-controlled phase 3 trial evaluated ongericimab, a novel monoclonal antibody targeting PCSK9 — the protein that degrades LDL receptors in the liver — in 139 Chinese statin-intolerant adults with primary hypercholesterolemia or mixed dyslipidemia. Participants were assigned 2:1 to receive ongericimab 150 mg or placebo subcutaneously every two weeks for 12 weeks, followed by 40 weeks of open-label ongericimab treatment.
The results were striking. Ongericimab produced a 66.2% greater reduction in LDL cholesterol compared to placebo at week 12 (p < 0.0001), with reductions maintained through week 52. Beyond LDL, the drug significantly lowered non-HDL cholesterol, apolipoprotein B (ApoB), total cholesterol, and lipoprotein(a) — a genetically determined cardiovascular risk factor notoriously difficult to treat. Treatment-emergent adverse events occurred at similar rates in both groups, indicating the drug was well tolerated.
These findings are clinically meaningful for several reasons. Lp(a) reduction is particularly notable, as few approved therapies reliably address this marker. The sustained effect over 52 weeks adds confidence that ongericimab could serve as a durable long-term option. If approved, it would be the first PCSK9 inhibitor specifically validated in Chinese statin-intolerant patients.
Caveats include the relatively small sample size of 139 patients, the lack of hard cardiovascular outcome data, and the study being conducted exclusively in a Chinese population, which may limit generalizability. Full trial data beyond the abstract was not available for this review.
Key Findings
- Ongericimab reduced LDL cholesterol by 66.2% vs placebo over 12 weeks in statin-intolerant patients.
- LDL reductions were sustained through week 52, supporting long-term durability of effect.
- Significant reductions also seen in Lp(a), ApoB, non-HDL-C, and total cholesterol.
- Adverse event rates were comparable between ongericimab and placebo groups.
- First phase 3 PCSK9 inhibitor trial validated specifically in Chinese statin-intolerant patients.
Methodology
Randomized, multicenter, double-blind, placebo-controlled phase 3 trial enrolling 139 Chinese adults assigned 2:1 to ongericimab 150 mg or placebo subcutaneously every 2 weeks for 12 weeks, followed by a 40-week open-label extension. Primary endpoint was percentage change in LDL-C from baseline to week 12.
Study Limitations
The trial enrolled only 139 patients, limiting statistical power for safety signals and subgroup analyses. The study was conducted exclusively in China, and results may not generalize to other ethnic populations. This summary is based on the abstract only, as the full paper was not available; detailed methodology, adverse event breakdowns, and subgroup data could not be assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.